Close this search box.

RockStep explores cutting-edge solutions for the in vivo lab of the future

A critical first step before moving to human clinical trials, in vivo studies are largely hands-on and often depend on manual or basic data capture processes, including handwritten notes, spreadsheets, or in-house legacy systems. But the future holds a whole new reality.

White Paper: Strategies for Effectively Leveraging Preclinical Data to Accelerate R&D

In vivo studies are considered crucial to drug discovery, yet bringing innovation into the lab has largely escaped advanced technologies that help streamline study workflows and improve research data capture processes. With processes largely manual or reliant on outdated or homegrown technologies, results can be notoriously difficult to reproduce, often due to human error, with 50-80% in vivo research considered unreproducible and representing an estimated $28 billion in losses for the industry.

This white paper is based on the insights of an esteemed industry panel hosted by RockStep and explores why capturing in vivo study data can be so challenging – and potentially costly – in the current model.

This paper explores:

Download the Whitepaper Now.



Strategies for Effectively Leveraging Preclinical Data to Accelerate R&D

This webinar hosted by Fierce Healthcare and sponsored by RockStep features a discussion with top industry leaders in the in vivo research space, including Chuck Donnelly, CEO and Co-Founder, RockStep Solutions; Amy Huff, Senior Director of Global Operations, Charles River Laboratories; Szczepan Baran, VMD/MS, Chief Scientific Officer, VeriSIM Life; Michael Hayward, PhD, Senior Director, In Vivo Pharmacology, JAX Mice, Clinical & Research Services, The Jackson Laboratory.

“In vivo research is considered the final frontier of informatics because it is so complex. Working with live organisms involves adapting to daily changes and the conflicting requirements of flexibility and precision,” 

Overcoming these barriers with standardization can improve the quality of in vivo data, explained Hayward, who noted that “clean data is collected under identical conditions with a standardized protocol.” He added that “Qualitative measures, which can be analyzed by parametric statistics, are preferred over subjective clinical observations.”

While reaping the benefits of standardization is feasible, it can be overwhelming due to the high number of legacy systems in use today. Explained Baran, part of the challenge is connecting these systems to gain actionable insights while also leveraging novel systems. “We can certainly learn from the clinical side,” he emphasized, as “there’s even more data from patient trials” to contend with.  “If it is feasible on the clinical side, it is feasible on the pre-clinical side,” he added.

Welcome Webinar Speaker Panel

Chuck Donnelly

CEO and Co-Founder

RockStep Solutions

Amy Huff

Senior Director of Global Operations

Charles River

Michael Hayward, PhD

Senior Director, In Vivo Pharmacology, JAX Mice, Clinical & Research Services

The Jackson Laboratory

Szczepan Baran

VMD/MS, Chief Scientific Officer

VeriSIM Life